Loss of EGF-dependent cell proliferation ability on radioresistant cell HepG2-8960-R

Yohei Saito, Ryo Abiko, Akira Kishida, Yoshikazu Kuwahara, Yumi Yamamoto, Fumihiko Yamamoto, Manabu Fukumoto, Yasuhito Ohkubo

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Acquired radioresistance of cancer cells interferes with radiotherapy and increases the probability of cancer recurrence. HepG2-8960-R, which is one of several clinically relevant radioresistant (CRR) cell lines, has a high tolerance to the repeated clinically relevant doses of X-ray radiation. In this study, HepG2-8960-R had slightly lower cell proliferation ability than HepG2 in the presence of FBS. In particular, epidermal growth factor (EGF) hardly enhanced cell proliferation and DNA synthesis in HepG2-8960-R. Additionally, EGF could not induce the activation of Erk1/2, because the expression of EGF receptor (EGFR) protein decreased in HepG2-8960-R in accordance with the methylation of the EGFR promoter region. Therefore, cetuximab did not inhibit HepG2-8960-R cell proliferation. Our study showed that HepG2-8960-R had radioresistant and cetuximab-resistant abilities.

Original languageEnglish
Pages (from-to)73-79
Number of pages7
JournalCell Biochemistry and Function
Issue number2
Publication statusPublished - 2015 Mar 1


  • Cetuximab
  • Hepatocellular carcinoma
  • Radiation
  • Radioresistance

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'Loss of EGF-dependent cell proliferation ability on radioresistant cell HepG2-8960-R'. Together they form a unique fingerprint.

Cite this